RetinalGenix Reports $590K Net Loss and No Revenue for Q1 2026

RetinalGenix Technologies Inc. reported a net loss of $590,489 for the three months ended March 31, 2026, slightly higher than the net loss of $587,259 recorded in the same period of the previous year. The company did not generate any revenue during this period, maintaining a consistent trend since its inception. Total operating expenses for the first quarter of 2026 were $589,229, which is marginally higher than the $586,350 reported in the first quarter of 2025. The increase in expenses was primarily driven by a significant rise in research and development costs, which surged by 786% to $117,064, compared to $13,214 in the prior year, as the company engaged engineering and technology consultants for its RetinalCam project.

In terms of operational changes, RetinalGenix has made strategic advancements in its product development. The company is preparing to launch its RetinalCam device, a portable ophthalmic screening tool, in the fourth quarter of 2026. Additionally, RetinalGenix is collaborating with Pearl IRB to conduct a study aimed at personalizing medical evaluations for patients receiving intraocular injections for wet macular degeneration. This study is expected to expand to multiple states by early 2027, which could enhance the company's clinical trial plans.

The company’s financial position remains precarious, with cash reserves dwindling to just $180 as of March 31, 2026, and total liabilities amounting to approximately $2.56 million. RetinalGenix has relied heavily on funding from related parties, particularly Sanovas, which has covered a significant portion of its operating expenses. The company is currently in discussions to raise additional capital, estimating a need for approximately $7 million to support ongoing product development and operational costs. However, there is substantial doubt regarding its ability to secure this funding, which raises concerns about its viability as a going concern.

RetinalGenix's employee headcount remains minimal, with no full-time employees reported, and the company continues to utilize personnel and resources from Sanovas. The company’s reliance on external funding and the lack of revenue generation highlight the challenges it faces in achieving profitability. The management has indicated that it expects to incur additional costs associated with operating as a public company, which could further strain its financial resources.

Looking ahead, RetinalGenix aims to complete the development of its products and secure necessary regulatory approvals, although it does not anticipate generating revenue from product sales until these milestones are achieved. The company’s future financial health will depend on its ability to raise capital and successfully commercialize its product offerings, which remain uncertain given the current market conditions and the company's financial status.